Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 20/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 19/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 12/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 10/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gw-328267 SCHEMBL1980933 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2B | |
| Gw-328267 SCHEMBL1983128 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2B | |
| Gw-328267 SCHEMBL29369354 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2B | |
| Gw-328267 SCHEMBL13268529 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2B | |
| Gw-328267 SCHEMBL4390982 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2B | |
| Gw-328267 SCHEMBL1983126 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2B | |
| Gw-328267 SCHEMBL13268494 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2B | |
| Gw-328267 SCHEMBL5089293 | 0.99 | ADORA2A (0.99) | ADORA2AADORA3ADORA1ADORA2B | |
| Gw-328267 SCHEMBL7228505 | 0.96 | ADORA2A (0.93) | ADORA2AADORA3ADORA1ADORA2B | |
| Gw-328267 SCHEMBL7224617 | 0.96 | ADORA2A (0.93) | ADORA2AADORA3ADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240180854-A1 | USE OF BETA-ADRENERGIC INVERSE AGONISTS FOR SMOKING CESSATION | INVION INC (AU) | 2024-06-06 | — | — | US | claimed |
| CN-106390128-B | Use of beta-adrenergic inverse agonists for smoking cessation | 伊沃恩有限公司 | 2022-07-08 | — | — | CN | claimed |
| EP-3513787-A1 | USE OF BETA-ADRENERGIC INVERSE AGONISTS FOR SMOKING CESSATION | Invion, Inc (AU) | 2019-07-24 | — | — | EP | claimed |
| EP-2665741-A2 | USE OF BETA-ADRENERGIC INVERSE AGONISTS FOR SMOKING CESSATION | Invion, Inc (AU) | 2013-11-27 | — | — | EP | claimed |
| EP-2509606-A1 | NOVEL MEDICAL USE | Glaxo Group Limited (GB) | 2012-10-17 | — | — | EP | claimed |
| US-20120238520-A1 | Novel Medical Use | GLAXO GROUP LIMITED (GB) | 2012-09-20 | — | — | US | claimed |
| WO-2012096866-A2 | USE OF BETA-ADRENERGIC INVERSE AGONISTS FOR SMOKING CESSATION | INVERSEON, INC. (US) | 2012-07-19 | — | — | WO | claimed |
| WO-2011069918-A1 | NOVEL MEDICAL USE | GLAXO GROUP LIMITED (GB) | 2011-06-16 | — | — | WO | claimed |
| US-20100105758-A1 | USE OF AN ADENOSINE ANTAGONIST | CENTRE DE RECHERCHE PUBLIC DE LA SANTE (LU) | 2010-04-29 | — | — | US | claimed |
| JP-4156035-B2 | — | — | 2008-09-24 | — | — | JP | claimed |
| WO-2002072067-A2 | PHARMACEUTICAL AEROSOL FORMULATION | GLAXO GROUP LIMITED (GB) | 2002-09-19 | — | — | WO | claimed |
| WO-2002067909-A1 | NEW METHOD OF BRONCHODILATORY THERAPY | GLAXO GROUP LIMITED (GB) | 2002-09-06 | — | — | WO | claimed |
| US-6426337-B1 | ANTIINFLAMMATORY AGENTS | SMITHKLINE BEECHAM CORPORATION | 2002-07-30 | — | — | US | claimed |
| US-20020086850-A1 | 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives | COX BRIAN (GB) | 2002-07-04 | — | — | US | claimed |
| WO-2002000200-A1 | NOVEL PROCESS FOR PREPARING CRYSTALLINE PARTICLES | GLAXO GROUP LIMITED (GB) | 2002-01-03 | — | — | WO | claimed |
| JP-2001506668-A | — | — | 2001-05-22 | — | — | JP | claimed |
| EP-1090022-A1 | 2-(PURIN-9-YL)-TETRAHYDROFURAN-3,4-DIOL DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2001-04-11 | — | — | EP | claimed |
| WO-1999067265-A1 | 2-(PURIN-9-YL)-TETRAHYDROFURAN-3,4-DIOL DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1999-12-29 | — | — | WO | claimed |
| EP-0948509-A1 | 2-(PURIN-9-YL)-TETRAHYDROFURAN-3,4-DIOL DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1999-10-13 | — | — | EP | claimed |
| WO-1998028319-A1 | 2-(PURIN-9-YL)-TETRAHYDROFURAN-3,4-DIOL DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1998-07-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086850-A1 | 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives | PURB, P2RX3, P2RY2 | ADORA2A 202/4885ADORA3 182/4885ADORA1 135/4885 |
| US-20120238520-A1 | Novel Medical Use | FPR3, PTGES3, FPR2 | ADORA2A 87/4885ADORA3 63/4885ADORA1 142/4885 |
| US-20240180854-A1 | USE OF BETA-ADRENERGIC INVERSE AGONISTS FOR SMOKING CESSATION | ADRB1, ADRB2, ADRB3 | ADORA2A 225/4885ADORA3 107/4885ADORA1 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.